IE58805B1 - Use of dipeptide derivatives for the production of medicines for the prevention or treatment of posttraumatic nerve damage after spinal cord and/or brain trauma caused by an accident - Google Patents
Use of dipeptide derivatives for the production of medicines for the prevention or treatment of posttraumatic nerve damage after spinal cord and/or brain trauma caused by an accidentInfo
- Publication number
- IE58805B1 IE58805B1 IE290585A IE290585A IE58805B1 IE 58805 B1 IE58805 B1 IE 58805B1 IE 290585 A IE290585 A IE 290585A IE 290585 A IE290585 A IE 290585A IE 58805 B1 IE58805 B1 IE 58805B1
- Authority
- IE
- Ireland
- Prior art keywords
- traumas
- prevention
- treatment
- accident
- medicines
- Prior art date
Links
- 210000000278 spinal cord Anatomy 0.000 title claims abstract description 24
- 230000002265 prevention Effects 0.000 title claims abstract description 22
- 208000030886 Traumatic Brain injury Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 208000028389 Nerve injury Diseases 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title claims abstract description 18
- 230000008764 nerve damage Effects 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 108010016626 Dipeptides Proteins 0.000 title claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 11
- 150000007513 acids Chemical class 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 208000014674 injury Diseases 0.000 claims description 29
- 230000008733 trauma Effects 0.000 claims description 29
- 208000024891 symptom Diseases 0.000 claims description 15
- 230000000472 traumatic effect Effects 0.000 claims description 14
- 206010033892 Paraplegia Diseases 0.000 claims description 13
- 230000007812 deficiency Effects 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000011149 active material Substances 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 description 23
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 12
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 12
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 12
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- 208000009893 Nonpenetrating Wounds Diseases 0.000 description 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013509 Disturbances in consciousness Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000004776 neurological deficiency Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/066—TRH, thyroliberin, thyrotropin releasing hormone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853502041 DE3502041A1 (de) | 1985-01-23 | 1985-01-23 | Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE852905L IE852905L (en) | 1986-07-23 |
| IE58805B1 true IE58805B1 (en) | 1993-11-17 |
Family
ID=6260477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE290585A IE58805B1 (en) | 1985-01-23 | 1985-11-19 | Use of dipeptide derivatives for the production of medicines for the prevention or treatment of posttraumatic nerve damage after spinal cord and/or brain trauma caused by an accident |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4906614A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0188810B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPS61172828A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE57834T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU578999B2 (cg-RX-API-DMAC7.html) |
| DE (2) | DE3502041A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK165733C (cg-RX-API-DMAC7.html) |
| IE (1) | IE58805B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL77218A (cg-RX-API-DMAC7.html) |
| SG (1) | SG83791G (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA859187B (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960002182B1 (ko) * | 1987-04-08 | 1996-02-13 | 닛본 신야쿠 가부시기가이샤 | 향지성제 |
| US5686420A (en) * | 1987-06-05 | 1997-11-11 | Georgetown University | Thyrotropin-releasing hormone analogs and method of use |
| JPS63316724A (ja) * | 1987-06-19 | 1988-12-26 | Nippon Shinyaku Co Ltd | 抗けいれん剤 |
| US5049553A (en) * | 1990-01-04 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Method for preventing or treating symptoms resulting from closed head injuries employing an ace inhibitor |
| JPH09509404A (ja) * | 1993-12-23 | 1997-09-22 | オークランド ユニサービシズ リミテッド | 神経アウトカムを改良するための組成物及び方法 |
| US6812208B2 (en) | 1993-12-23 | 2004-11-02 | Neuronz Ltd. | Methods to improve neural outcome |
| US5897858A (en) | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| US6187906B1 (en) * | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
| US20050233973A1 (en) * | 1997-10-09 | 2005-10-20 | Albert Sattin | Tri-peptides for antidepressant applications |
| US6475989B1 (en) | 1997-10-09 | 2002-11-05 | Albert Sattin | Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders |
| US20020151502A1 (en) * | 1997-10-09 | 2002-10-17 | Albert Sattin | Tri-peptides for neurological and neurobehavior applications |
| AU1574701A (en) * | 1999-10-22 | 2001-04-30 | Wrair Walter Reed Army Institute Of Research | A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| US6815425B1 (en) | 1999-10-22 | 2004-11-09 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| IE20000240A1 (en) * | 2000-02-17 | 2003-03-05 | Trinity College Dublin | TRH-like peptide derivatives |
| WO2002016408A2 (en) * | 2000-08-24 | 2002-02-28 | Neuronz Ltd. | Gpe analogs |
| US7112570B2 (en) * | 2000-08-24 | 2006-09-26 | Neuren Pharmaceuticals, Ltd. | GPE analogs |
| DE60232880D1 (de) | 2001-05-24 | 2009-08-20 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
| US7714020B2 (en) * | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7605177B2 (en) * | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
| US8791117B2 (en) | 2003-09-03 | 2014-07-29 | Neuren Pharmaceuticals Limited | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals |
| US7462595B2 (en) * | 2004-09-17 | 2008-12-09 | Prange Jr Arthur Jergen | Methods for treating cancer-related fatigue |
| ES2546015T3 (es) * | 2004-10-01 | 2015-09-17 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compuestos que modulan acciones de THR e inhiben la enzima de degradación de TRH |
| LT3024463T (lt) | 2013-07-25 | 2020-07-10 | Neuren Pharmaceuticals Limited | Neuroapsauginiai bicikliniai junginiai ir jų panaudojimo būdai autizmo spektro sutrikimų ir neuroliginių vystymosi sutrikimų gydymui |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2449167C2 (de) | 1974-10-16 | 1984-05-24 | Grünenthal GmbH, 5190 Stolberg | N-Acyl-L-histidyl-L-prolinamide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| DE2615455C2 (de) | 1976-04-09 | 1985-06-20 | Grünenthal GmbH, 5190 Stolberg | N-Acyl-L-histidyl-L-prolin (N-substituierte)-amide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| US4608365A (en) * | 1984-03-30 | 1986-08-26 | University Of Southern California | Treatment of neurologic functions |
-
1985
- 1985-01-23 DE DE19853502041 patent/DE3502041A1/de not_active Withdrawn
- 1985-11-19 IE IE290585A patent/IE58805B1/en not_active IP Right Cessation
- 1985-11-29 ZA ZA859187A patent/ZA859187B/xx unknown
- 1985-12-03 IL IL77218A patent/IL77218A/xx not_active IP Right Cessation
- 1985-12-23 DE DE8585116530T patent/DE3580351D1/de not_active Expired - Lifetime
- 1985-12-23 EP EP85116530A patent/EP0188810B1/de not_active Expired - Lifetime
- 1985-12-23 AT AT85116530T patent/ATE57834T1/de not_active IP Right Cessation
-
1986
- 1986-01-22 DK DK032786A patent/DK165733C/da not_active IP Right Cessation
- 1986-01-22 AU AU52601/86A patent/AU578999B2/en not_active Ceased
- 1986-01-23 JP JP61011187A patent/JPS61172828A/ja active Granted
-
1988
- 1988-06-14 US US07/207,115 patent/US4906614A/en not_active Expired - Lifetime
-
1991
- 1991-10-11 SG SG837/91A patent/SG83791G/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE852905L (en) | 1986-07-23 |
| DK32786A (da) | 1986-07-24 |
| EP0188810A3 (en) | 1988-09-07 |
| IL77218A (en) | 1990-11-05 |
| AU578999B2 (en) | 1988-11-10 |
| US4906614A (en) | 1990-03-06 |
| EP0188810B1 (de) | 1990-10-31 |
| DK32786D0 (da) | 1986-01-22 |
| ATE57834T1 (de) | 1990-11-15 |
| SG83791G (en) | 1991-11-22 |
| EP0188810A2 (de) | 1986-07-30 |
| DK165733C (da) | 1993-06-07 |
| ZA859187B (en) | 1986-08-27 |
| JPS61172828A (ja) | 1986-08-04 |
| DK165733B (da) | 1993-01-11 |
| AU5260186A (en) | 1986-07-31 |
| DE3580351D1 (de) | 1990-12-06 |
| JPH0584286B2 (cg-RX-API-DMAC7.html) | 1993-12-01 |
| DE3502041A1 (de) | 1986-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE58805B1 (en) | Use of dipeptide derivatives for the production of medicines for the prevention or treatment of posttraumatic nerve damage after spinal cord and/or brain trauma caused by an accident | |
| JPS6075454A (ja) | 鎮痛用新規化合物および組成物 | |
| WO2011098539A1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| IE58849B1 (en) | Use of dipeptide derivatives for the manufacture of medicaments for the treatment of patients with amyotrophic lateral sclerosis | |
| HU226555B1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| JP2004026678A (ja) | ２型糖尿病治療剤 | |
| US3557292A (en) | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine | |
| EP0147185A2 (en) | Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine | |
| JPH045231A (ja) | 慢性痛用鎮痛剤 | |
| AU2001266441A1 (en) | Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use | |
| DE2455203A1 (de) | Pharmazeutisches mittel mit einem gehalt an p-hydroxyacetanilid | |
| MX2007001348A (es) | Composiciones de vitamina b12. | |
| EA002023B1 (ru) | Фармацевтическая композиция местного применения для введения в живой организм, содержащая пептидное лекарственное средство | |
| US3917836A (en) | Antitussivum | |
| JPH0518811B2 (cg-RX-API-DMAC7.html) | ||
| JPH05508657A (ja) | 加速度病に関連する悪心および嘔吐の治療方法 | |
| CA2547873A1 (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
| US11446264B2 (en) | Memory manipulation via modification of protein kinase C zeta activity | |
| EP4173624A1 (en) | Ameliorating agent or prophylactic agent for muscle weakness symptom in disease or syndrome associated with metabolic disorder | |
| WO2022256097A1 (en) | Method of dosing a pain therapeutic | |
| JPS62501629A (ja) | 医薬、ビタミンまたはワクチンの筋肉注射用製剤 | |
| WO2025198489A1 (ru) | Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения | |
| Wong et al. | Biphasic emetic response of cyclophosphamide in the ferret | |
| KR920700041A (ko) | 치료화합물과 그의 조성 및 용도 | |
| JPS58225015A (ja) | 硬化症治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |